Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)

Table 4

Changes in inflammatory markers.

Parameters	Group	0 month	12 months	P-value	Difference	P-value
Hyaluronic acid (ng/mL)	T	38.3±29.1	51.9±41.3	0.091	13.6±23.9
	L	57.5±46.2	60.1±44.5	0.345	2.6±5.8	0.310
7S domain of type 4 collagen (ng/mL)	T	4.4±0.7	4.5±1.7	0.723	0.07±1.46
	L	4.4±0.9	4.4±0.9	0.834	0.03±0.44	0.419
High-sensitivity C-reactive protein (mg/dL)	T	0.13±0.10	0.20±0.14	0.155	0.09±0.15
	L	0.13±0.12	0.11±0.09	0.176	−0.02±0.04	0.077
Procollagen-3-peptide (U/mL)	T	0.57±0.09	0.57±0.13	0.656	−0.003±0.134
	L	0.51±0.05	0.49±0.11	0.351	−0.023±0.098	0.766
Zinc (μg/dL)	T	88.8±13.9	85.1±17.7	0.139	−3.8±7.8
	L	88.0±17.1	89.1±15.6	0.735	1.1±12.3	0.374
Total adiponectin (μg/mL)	T	7.3±1.5	7.1±2.1	0.553	−0.2±0.9
	L	7.8±1.1	8.3±1.5	0.753	0.5±2.1	0.561
Interleukin-6 (pg/mL)	T	3.4±5.5	2.5±0.8	0.158	−0.9±5.9
	L	1.7±1.0	2.3±1.8	0.173	0.6±1.0	0.766

Data are presented as mean ± SD. Parameters at 0 and 12 months of treatment were compared by Wilcoxon's matched-pair signed-rank test. Differences are shown as [value at 12 months − value at 0 month]. Differences between groups (telmisartan (T) versus losartan (L)) were compared by Mann-Whitney 𝑈 test.